Higher Costs, Higher Fees, Higher Drug Prices: The UK No-Deal Brexit Bonus

 
• By Ian Schofield
  
EU_UK
The UK will set up its own drug approval procedures in the event of a no-deal Brexit

More from Regulation

More from Policy & Regulation